<oai_dc:dc xmlns:dc="http://purl.org/dc/elements/1.1/" xmlns:oai_dc="http://www.openarchives.org/OAI/2.0/oai_dc/" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:schemaLocation="http://www.openarchives.org/OAI/2.0/oai_dc/ http://www.openarchives.org/OAI/2.0/oai_dc.xsd">
  <dc:source xml:lang="eng">MEMO - Magazine of European Medical Oncology</dc:source>
  <dc:format>application/pdf</dc:format>
  <dc:format>application/pdf</dc:format>
  <dc:title xml:lang="eng">15 years Ludwig Boltzmann Institute for Hematology and Oncology (LBI HO): achievements and future perspectives</dc:title>
  <dc:type xml:lang="deu">Text</dc:type>
  <dc:type xml:lang="deu">Wissenschaftlicher Artikel</dc:type>
  <dc:rights>http://creativecommons.org/licenses/by/4.0/</dc:rights>
  <dc:description xml:lang="eng">Cancer stem cells, also known as leukemic stem cells (LSC) in the context of leukemias, are an emerging topic in translational oncology and hematology. The Ludwig Boltzmann Institute for Hematology and Oncology (LBI HO) was established in 2008 with the aim to translate LSC concepts into clinical practice. Major specific aims of the LBI HO are to identify LSC in various blood cell disorders and to improve anti-leukemic therapies by establishing LSC-targeting and LSC-eradicating approaches with the ultimate aim to translate these concepts into clinical practice. In addition, the LBI HO identified a number of diagnostic and prognostic LSC markers in various blood cell malignancies. Members of the LBI HO have also developed precision medicine tools and personalized medicine approaches around LSC in applied hematology. As a result, diagnosis, prognostication and therapy have improved in the past 10 years. Major disease models are myeloid leukemias and mast cell neoplasms. Finally, the LBI HO consortium launched several projects in the field of open innovation in science where patient-derived initiatives and their input supported the scientific community. Key aims for the future of the LBI HO are to develop LSC-related concepts and strategies further, with the long-term vision to cure more patients with hematologic malignancies.</dc:description>
  <dc:subject xml:lang="eng">Acute Myeloid-Leukemia</dc:subject>
  <dc:subject xml:lang="eng">Cancer Stem-Cells</dc:subject>
  <dc:subject xml:lang="eng">Therapeutic Target</dc:subject>
  <dc:subject xml:lang="eng">Initiating Cells</dc:subject>
  <dc:subject xml:lang="eng">Progenitor Cells</dc:subject>
  <dc:subject xml:lang="eng">Melanoma-Cells</dc:subject>
  <dc:subject xml:lang="eng">Kinase Domain</dc:subject>
  <dc:subject xml:lang="eng">Identification</dc:subject>
  <dc:subject xml:lang="eng">Midostaurin</dc:subject>
  <dc:subject xml:lang="eng">Heterogeneity</dc:subject>
  <dc:type xml:lang="eng">Text</dc:type>
  <dc:type xml:lang="eng">journal article</dc:type>
  <dc:identifier>doi:10.1007/s12254-024-00966-w</dc:identifier>
  <dc:creator>Peter Valent</dc:creator>
  <dc:creator>Emir Hadzijusufovic</dc:creator>
  <dc:creator>Irina Sadovnik</dc:creator>
  <dc:creator>Thomas W. Grunt</dc:creator>
  <dc:creator>Barbara Peter</dc:creator>
  <dc:creator>Michael Willmann</dc:creator>
  <dc:creator>Harald Herrmann</dc:creator>
  <dc:creator>Daniel Ivanov</dc:creator>
  <dc:creator>Gregor Eisenwort</dc:creator>
  <dc:creator>Heidrun Karlic</dc:creator>
  <dc:creator>Georg Greiner</dc:creator>
  <dc:creator>Karoline V. Gleixner</dc:creator>
  <dc:creator>Thomas Rülicke</dc:creator>
  <dc:creator>Maik Dahlhoff</dc:creator>
  <dc:creator>Philipp Staber</dc:creator>
  <dc:creator>Wolfgang R. Sperr</dc:creator>
  <dc:creator>Michael Pfeilstöcker</dc:creator>
  <dc:creator>Thomas Lion</dc:creator>
  <dc:creator>Felix Keil</dc:creator>
  <dc:creator>Gregor Hoermann</dc:creator>
  <dc:language>eng</dc:language>
  <dc:publisher>Springer</dc:publisher>
  <dc:date>2024</dc:date>
  <dc:rights xml:lang="eng">Copyright © 2024, The Author(s)</dc:rights>
  <dc:rights xml:lang="eng">open access</dc:rights>
  <dc:identifier>https://phaidra.vetmeduni.ac.at/o:3713</dc:identifier>
</oai_dc:dc>